Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Day One Biopharmaceuticals, Inc. (DAWN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.45-0.29 (-1.33%)
At close: 04:00PM EST
21.55 +0.10 (+0.47%)
After hours: 07:53PM EST
Advertisement

Day One Biopharmaceuticals, Inc.

395 Oyster Point Boulevard
Suite 217
South San Francisco, CA 94080
United States
650 484 0899
https://dayonebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees102

Key Executives

NameTitlePayExercisedYear Born
Dr. Jeremy Bender M.B.A., Ph.D.CEO, Pres & Director836.82kN/A1972
Dr. Samuel C. Blackman M.D., Ph.D.Co-Founder & Chief Medical Officer627.57kN/A1969
Ms. Julie Papanek Grant M.B.A.Co-Founder & Director41.81kN/A1982
Mr. Charles N. York IICOO, CFO & Sec.714.34kN/A1977
Dr. Mike Preigh Ph.D.Chief of Technology OperationsN/AN/AN/A
Mr. Adam DubowGen. CounselN/AN/A1967
Ms. Jaa RobersonChief People OfficerN/AN/AN/A
Dr. Davy Chiodin Ph.D., Pharm.D.Chief Devel. OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate Governance

Day One Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement